Gosegyne

Gosegyne is an oral medication that contains progesterone, a naturally occurring progestogen. Marketed in the European Union, Gosegyne is supplied without a specified strength and is classified under hormone therapy as a progesterone receptor agonist. It is intended for use under medical supervision as part of hormone management strategies, and is administered by mouth in clinical contexts where progesterone supplementation may be required appropriately and safely.

Gosegyne is used in hormone therapy where progesterone supplementation is clinically indicated. Its oral formulation allows systemic delivery of progesterone for various therapeutic purposes.

- Management of luteal phase deficiency in assisted reproductive cycles. - Support of the luteal phase in natural menstrual cycles. - Adjunct therapy in hormone replacement regimens for menopausal women. - Treatment of certain menstrual disorders associated with low progesterone levels. - Part of a combined regimen for prevention of endometrial hyperplasia in women receiving estrogen therapy.

Side effects reported with oral progesterone products such as Gosegyne vary in frequency and severity.

Common: - Mild nausea or gastrointestinal discomfort. - Headache or dizziness. - Breast tenderness or swelling.

Serious: - Signs of allergic reaction such as rash, itching, or swelling of the face. - Unexplained vaginal bleeding. - Symptoms of thromboembolic events, including leg pain or swelling and shortness of breath.

When considering Gosegyne, clinicians evaluate several precautionary factors to ensure safe use.

- Assess personal and family history of thromboembolic disease before initiating therapy. - Review liver function, as progesterone metabolism occurs hepatically. - Evaluate for known hypersensitivity to progesterone or excipients. - Consider potential effects on mood or depressive symptoms, especially in patients with a history of mood disorders. - Use caution in patients with uncontrolled hypertension or cardiovascular disease. - Discuss pregnancy intentions, since progesterone supplementation may affect fetal development.

Gosegyne may interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce progesterone levels. - Combination with anticoagulants that increase bleeding risk when hormonal effects alter coagulation.

Use with caution: - Co‑administration with other hormonal agents (e.g., estrogen, progestin) may require dose adjustments. - Use alongside medications that affect hepatic metabolism (e.g., certain antifungals) may alter progesterone concentrations. - Patients taking sedatives should be monitored for additive central nervous system effects.